Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Abstract Background: Clinicians in pulmonary critical care medicine and critical care
medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is
useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3
(NLRP3).
Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3
inflammasome by dapsone must be responsible for its observed preventive effects, functioning
as a competitor.
Methods:
Patients who were on standard COVID-19 therapy are also after obtaining off label uses and
explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400
mg three times daily.